id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-308313-3speddao	Jaspard, Marie	Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France	2020-08-17		.txt	text/plain	4288	213	43	In 33 (58%) patients, neurologic or ophthalmologic signs developed, and 18 (32%) had confirmed peripheral neuropathy, which for 78% was irreversible at 12 months after the end of TB treatment despite linezolid withdrawal. In 33 (58%) patients, neurologic or ophthalmologic signs developed, and 18 (32%) had confirmed peripheral neuropathy, which for 78% was irreversible at 12 months after the end of TB treatment despite linezolid withdrawal. We therefore evaluated the occurrence and management of neurologic and ophthalmologic adverse effects among MDR TB patients receiving a linezolid-based treatment regimen. Among the 16 (33%) patients with trough concentrations >2 mg/L (median 3 [IQR 2.4-3.7] mg/L) at least once at baseline or during treatment, 14 (88%) experienced linezolid-associated adverse effects: 9 had a peripheral neuropathy and 5 had optical neuropathy. In our study, 58% of MDR/XDR TB patients reported a neurologic or ophthalmologic disorder possibly associated with linezolid exposure; neuropathies were confirmed for 47%.	./cache/cord-308313-3speddao.txt	./txt/cord-308313-3speddao.txt